Lisata Therapeutics, Inc. (NASDAQ: LSTA)

Lisata Therapeutics, Inc. (not to be confused with LTX-109, a separate company listed on NASDAQ under the symbol "LNTH") operates in the pharmaceutical industry, which is highly regulated by various governmental agencies such as the U.S. Food and Drug Administration (FDA). The company's primary business activities involve the development of pharmaceutical products, with its lead investigational product candidate, LSTA1, currently in Phase 2a and 2b clinical trials.

Lisata Therapeutics generates revenue through the development and commercialization of its pharmaceutical products. LSTA1 is the company's primary product candidate, and it has the potential to be combined with various anti-cancer agents to treat a range of solid tumor types, including pancreatic cancer. The company is also exploring opportunities for technology collaboration and out-licensing with other pharmaceutical companies.

LSTA1 is an investigational drug candidate that actuates the CendR active transport mechanism. It targets tumor vasculature, endothelial cells, tumor cells, and some intratumoral immunosuppressive cells by its affinity for alpha-v, beta-3, and beta-5 integrins that are upregulated on these cells. LSTA1 has demonstrated favorable safety, tolerability, and activity in clinical trials to enhance delivery of standard-of-care chemotherapy for pancreatic cancer.

Pancreatic cancer is a significant unmet medical need, with approximately 64,000 new cases diagnosed annually in the United States and over 397,000 worldwide. LSTA1 has the potential to be combined with various anti-cancer agents to treat pancreatic ductal adenocarcinoma (PDAC) and other advanced solid tumors.

The healthcare industry is one of the most highly regulated industries in the United States and abroad. Lisata Therapeutics is subject to various federal and state statutes and regulations, including the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other global agencies. The company must comply with good laboratory practice (GLP) regulations, good clinical practices (GCPs), and current Good Manufacturing Practices (cGMPs) to ensure the quality and safety of its products.

Lisata Therapeutics is also subject to various expedited review programs, including the Fast Track, Breakthrough Therapy, and Priority Review Designations, which can expedite the development and review of its product candidates. Additionally, the company is subject to post-approval requirements, including reporting of adverse experiences, product sampling and distribution restrictions, and compliance with advertising and promotion requirements.

Lisata Therapeutics' position within the industry is unique, with a focus on developing innovative therapies for the treatment of solid tumors and other major diseases. The company's product candidates are still in development, and its competitive advantages include its focus on developing innovative therapies and its ability to leverage its expertise in the field of solid tumors and other major diseases.

The company's customers are primarily healthcare professionals and patients who are seeking treatment for solid tumors and other major diseases. Lisata Therapeutics works closely with its customers to understand their needs and to develop therapies that meet those needs.